Sebotar Topical Solution
Product introduction
Sebotar Topical Solution is only meant for external use and should be used as advised by your doctor. A thin layer of the medicine should be applied only to the affected areas of the skin with clean and dry hands. Wash your hands before and after application of the medicine. If it gets into your eyes, nose, or mouth rinse with water. It may take several days to weeks for your symptoms to improve, but you should keep using this medicine regularly. The course of the treatment should be completed to ensure better efficacy of the medicine.
This medicine is usually safe, however, it may cause burning, irritation, itching, and redness at the application site. These side effects are usually mild and self-limiting. Serious side effects are rare.
It is not likely that other medicines you take by mouth or injection will affect the way this medicine works, but talk to your doctor before using it if you have recently used another medicine for the dandruff. The medicine is not recommended for pregnant women. Pregnant and breastfeeding mothers should consult their doctors before using this medicine.
Uses of Sebotar Solution
Benefits of Sebotar Solution
In Treatment of Dandruff
Side effects of Sebotar Solution
Common side effects of Sebotar
- Application site reactions (burning, irritation, itching and redness)
How to use Sebotar Solution
How Sebotar Solution works
Safety advice
What if you forget to take Sebotar Solution?
All substitutes
Quick tips
- Sebotar Topical Solution must be applied on the affected area as prescribed by your doctor.
- Take care to avoid getting it in your eyes. If accidental exposure occurs, rinse immediately with plenty of water.
- Do not use this medicine more often or for longer than advised by your doctor.
- Before each application, wash the affected area with soap and water and dry well.
- Stop using Sebotar Topical Solution and inform your doctor if you notice any irritation or any other skin infection.
- Inform your doctor if the treated skin area does not improve after 2-4 weeks of treatment.
Fact Box
Patient concerns
User feedback
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Fox LP, Merk HF, Bickers DR. Dermatological Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1679-1706.
- Robertson DB, Maibach HI. Dermatologic Pharmacology. In: Katzung BG, Masters SB, Trevor AJ (Editors). Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 1047-1065.
Marketer details
The list of available options shown with the same composition has been prepared upon the advice of registered medical practitioners, pharmacists affiliated with TATA 1MG. TATA 1MG does not promote any pharmaceutical product of any particular company, and all recommendations are based on the medical opinion, advisories from specialist medical and pharmaceutical professionals.